Novel N-substituted indole Schiff bases as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase enzymes: Synthesis, biological activities in vitro and docking study

European Journal of Medicinal Chemistry

Volumn 123, Issue , 2016, Pages 803-813

  Lamie, Phoebe F ^a   Ali, Waleed A M ^b   Bazgier, Vaclav ^c,d   Rárová, Lucie ^c  

^a Beni Suef University   (Egypt)

^b Cairo General Hospital   (Egypt)

^c INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

^d PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Anti inflammatory activity; Antiproliferative activity; Cyclooxygenase enzymes; Indole derivatives; Molecular docking study

Indexed keywords

1,5 DIMETHYL 4 [[(1 (4 METHYLBENZOYL) 1H INDOL 3YL)METHYLENE]AMINO] 1,5 DIMETHYL 2 PHENYL 1H PYRAZOL 3(2H) ONE; 2 [ [[(4H 1,2,4 TRIAZOL 4 YL)IMINO]METHYL] 1H INDOL 1YL] N (4 HYDROXYPHENYL)ACETAMIDE; 2 [3 [[(1,5 DIMETHYL 3 OXO 2 PHENYL 2,3 DIHYDRO 1H 4 YL)IMINO]METHYL] 1H INDOL 1YL] N (4 HYDROXYPHENYL)ACETAMIDE; 2 [3 [[(1,5 DIMETHYL 3 OXO 2 PHENYL 2,3 DIHYDRO 1H 4 YL)IMINO]METHYL] 1H INDOL 1YL] N (4 METHOXYPHENYL)ACETAMIDE; 2 [3 [[(1,5 DIMETHYL 3 OXO 2 PHENYL 2,3 DIHYDRO 1H 4 YL)IMINO]METHYL] 1H INDOL 1YL] N (4 TOLYL)ACETAMIDE; 2 [3 [[(1,5 DIMETHYL 3 OXO 2 PHENYL 2,3 DIHYDRO 1H 4 YL)IMINO]METHYL] 1H INDOL 1YL] N PHENYLACETAMIDE; 2 [3 [[(4H 1,2,4 TRIAZOL 4 YL)IMINO]METHYL] 1H INDOL 1YL] N (4 ACETYLPHENYL)ACETAMIDE; 2 [3 [[(4H 1,2,4 TRIAZOL 4 YL)IMINO]METHYL] 1H INDOL 1YL] N (4 METHOXYPHENYL)ACETAMIDE; 2 [3 [[(4H 1,2,4 TRIAZOL 4 YL)IMINO]METHYL] 1H INDOL 1YL] N (4 TOLYL)ACETAMIDE; 2 [3 [[(4H 1,2,4 TRIAZOL 4 YL)IMINO]METHYL] 1H INDOL 1YL] N PHENYLACETAMIDE; 4 [[(1 (4 CHLOROBENZOYL) 1H INDOL 3YL]METHYLENE]AMINO] 1,5 DIMETHYL 2 PHENYL 1H PYRAZOL 3(2H) ONE; 4 [[(1 BENZOYL 1H INDOL 3YL)METHYLENE]AMINO] 1,5 DIMETHYL 2 PHENYL 1H PYRAZOL 3(2H) ONE; 4 [[(1 BENZYL 1H INDOL 3YL)METHYLENE]AMINO] 1,5 DIMETHYL 2 PHENYL 1H PYRAZOL 3(2H) ONE; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ETHYL 4 [2 [3 [[(1,5 DIMETHYL 3 OXO 2 PHENYL 2,3 DIHYDRO 1H 4 YL)IMINO]METHYL] 1H INDOL 1YL]ACETAMIDO]BENZOATE; ETHYL 4 [2 [3 [[(4H 1,2,4 TRIAZOL 4 YL)IMINO]METHYL] 1H INDOL 1YL]ACETAMIDO]BENZOATE; INDOLE DERIVATIVE; INDOMETACIN; LIPOXYGENASE INHIBITOR; N (4 ACETYLPHENYL) 2 [3 [[(1,5 DIMETHYL 3 OXO 2 PHENYL 2,3 DIHYDRO 1H 4 YL)IMINO]METHYL] 1H INDOL 1YL]ACETAMIDE; N [(1 BENZOYL 1H INDOL 3YL)METHYLENE] 4H 1,2,4 TRIAZOL 4 AMINE; N [(1 BENZYL 1H INDOL 3 YL)METHYLENE] 4H 1,2,4 TRIAZOL 4 AMINE; N [[1 (4 METHYLBENZOYL) 1H INDOL 3YL]METHYLENE] 4H 1,2,4 TRIAZOL 4 AMINE; N [[1(4 CHLOROBENZOYL) 1H INDOL3YL]METHYLENE] 4H 1,2,4 TRIAZOL 4 AMINE; QUERCETIN; SCHIFF BASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INFRARED SPECTROSCOPY; MOLECULAR DOCKING; PROTON NUCLEAR MAGNETIC RESONANCE; SELECTIVITY INDEX; CHEMISTRY; DRUG DESIGN; METABOLISM; SYNTHESIS; TUMOR CELL LINE;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ARACHIDONATE 5-LIPOXYGENASE; CATALYTIC DOMAIN; CELL LINE, TUMOR; CHEMISTRY TECHNIQUES, SYNTHETIC; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG DESIGN; HUMANS; INDOLES; LIPOXYGENASE INHIBITORS; MOLECULAR DOCKING SIMULATION; SCHIFF BASES;

EID: 84982162829     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.08.013     Document Type: Article

References (37)

1. [1] Verma, L., Wakode, S., Synthesis and characterisation of 3-acetylindole derivatives and evaluation of their anti-inflammatory and anti-microbial activity. Pharma Innov. J. 2 (2013), 41–50.
2. [2] Paulose-Ram, R., Hirsch, R., Dillon, C., Gu, Q., Frequent monthly use of selected non-prescription and prescription non-narcotic analgesics among U.S. adults. Pharmacoepidemiol. Drug Saf. 14 (2005), 257–266.
3. [3] Lai, Y., Mab, L., Huang, W., Yu, X., Zhang, Y., Ji, H., Tian, J., Synthesis and biological evaluation of 3-[4-(amino/methylsulfonyl)phenyl]methylene-indolin-2-one derivatives as novel COX-1/2 and 5-LOX inhibitors. Bioorg. Med. Chem. Lett. 20 (2010), 7349–7353.
4. [4] Moreau, A., Chen, Q.H., Rao, P.N.P., Knaus, E.E., Design, synthesis, and biological evaluation of (E)-3-(4-methanesulfonylphenyl)-2-(aryl)acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases. Bioorg. Med. Chem. 14 (2006), 7716–7727.
5. [5] Chowdhury, M.A., Abdellatif, K.R.A., Dong, Y., Das, D., Suresh, M.R., Knaus, E.E., Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. J. Med. Chem. 52 (2009), 1525–1529.
6. [6] Charlier, C., Michaux, C., Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem. 38 (2003), 645–788.
7. [7] Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, J., Perkins, W., Lee, L., Isakson, P.C., Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 12013–12017.
8. [8] Penning, T.D., Talley, J.J., Bertenshaw, S.R., Carter, J.S., Collins, P.W., Docter, S., Graneto, M.J., Lee, L.F., Malecha, J.W., Miyashiro, J.M., Rogers, R.S., Rogier, D.J., Yu, S.S., Anderson, G.D., Burton, E.G., Cogburn, J.N., Gregory, S.A., Koboldt, C.M., Perkins, W.E., Seibert, K., Veenhuizen, A.W., Zhang, Y.Y., Isakson, P.C., Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 40 (1997), 1347–1365.
9. [9] Prasit, P., Wang, Z., Brideau, C., Chan, C.C., Charleson, S., Cromilish, W., Ethier, D., Evans, J.F., Ford-Hutchinson, A.W., Gauthier, J.Y., Gordon, R., Gyay, J., Gresser, M., Kargman, S., Kennedy, B., Leblanc, Y., Leger, S., Mancini, J., O'Neill, G.P., Ouellet, M., Percival, M.D., Perrier, H., Riendeau, D., Rodger, I., Tagari, P., Thierien, M., Vickers, P., Wong, E., Xu, L.-J., Young, R.N., Zamboni, R., The discovery of rofecoxib, [MK 966, Vioxx-, 4-( 4' -methylsulfo nylphenyl )- 3- phenyl- 2(5H)- furanone, an orally active Cyclooxygenase-2 inhibitor. Bioorg. Med. Chem. Lett. 9 (1999), 1773–1778.
10. [10] Grosser, T., Fries, S., Fitzgerald, G.A., Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116 (2006), 4–15.
11. [11] Badiger, J., Manjulatha, K., Girish, M., Sharif, A., Purohit, M.G., Synthesis and biological evaluation of some N-substituted indoles, Synthesis and biological evaluation of some N-substituted indoles. ARKIVOC xii (2009), 217–231.
12. [12] Meade, E.A., Smith, W.L., DeWitt, D.L., Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and OtherN on-steroidal antiinflammatory drug. J. Biol. Chem. 268 (1993), 6610–6614.
13. [13] Charlier, C., Michaux, C., Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem. 38 (2003), 645–659.
14. [14] Marnett, L.J., The COXIB experience: a look in the rearview mirror. Annu. Rev. Pharmacol. Toxicol. 49 (2009), 265–290.
15. [15] Kalva, S., Saleena, L.M., Pharmacophore Design, Homology and Docking Studies on 5-Lipoxygenase Inhibitors. International Conference on Bioscience, Biochemistry and Bioinformatics, vol. 5, 2011, 368–372.
16. [16] Vila, L., Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis. Med. Res. Rev. 24 (2004), 399–424.
17. [17] Zhao, L., Funk, C.D., Lipoxygenase pathways in atherogenesis. Trends Cardio Vasc. Med. 14 (2004), 191–195.
18. [18] Fiorucci, S., Meli, R., Bucci, M., Cirino, G., Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy. Biochem. Pharmacol. 62 (2001), 1433–1556.
19. [19] Khanna, S., Madan, M., Vangoori, A., Banerjee, R., Thaimattam, R., Basha, S.K.J., Ramesh, M., Casturi, S.R., Pal, M., Evaluation of glycolamide esters of indomethacin as potential cyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. 14 (2006), 4820–4833.
20. [20] Kalgutkar, A.S., Crews, B.C., Saleh, S., Prudhomme, D., Marnett, L.J., Indolyl esters and amides related to indomethacin are selective COX-2 inhibitors. Bioorg. Med. Chem. 13 (2005), 6810–6822.
21. [21] Chowdhury, M.A., Huang, Z., Abdellatif, K.R.A., Dong, Y., Yu, G., Velgzquez, C.A., Knaus, E.E., Synthesis and biological evaluation of indomethacin analogs possessing a N-difluoromethyl-1, 2-dihydropyrid-2-one ring system: a search for novel cyclooxygenase and lipoxygenase inhibitors. Bioorg. Med. Chem. Lett. 20 (2010), 5776–5780.
22. [22] Hu, W., Guo, Z., Chu, F., Bai, A., Yi, X., Cheng, G., Li, J., Synthesis and biological evaluation of substituted 2-sulfonyl-phenyl-3-phenyl-indoles: a new series of selective COX-2 inhibitors. Bioorg. Med. Chem. 11 (2003), 1153–1160.
23. [23] Bandgar, B.P., Sarangdhar, R.J., Viswakarma, S., Ahamed, F.A., Synthesis and biological evaluation of orally active prodrugs of indomethacin. J. Med. Chem. 54 (2011), 1191–1201.
24. [24] Kaur, J., Bhardwaj, A., Huang, Z., Knaus, E.E., N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: synthesis and biological evaluation. Bioorg. Med. Chem. Lett. 22 (2012), 2154–2159.
25. [25] Muri, E.M.F., Nieto, M.J., Sindelar, R.D., Williamson, J.S., Hydroxamic acids as pharmacological agents. Curr. Med. Chem. 9 (2002), 1631–1653.
26. [26] Hwang, S.H., Wecksler, A.T., Wagner, K., Hammock, B.D., Rationally designed multitarget agents against inflammation and pain. Curr. Med. Chem. 20 (2013), 1783–1799.
27. [27] Nelson, S.D., Structure toxicity relationships–how useful are they in predicting toxicities of new drugs. Adv. Exp. Med. Biol. 500 (2001), 33–43.
28. [28] Fouda, H.G., Avery, M.J., Dalvie, D., Falkner, F.C., Melvin, L.S., Ronfeld, R.A., Disposition and metabolism of tenidap in the rat. Drug Metab. Dispos. 25 (1997), 140–148.
29. [29] Abdellatif1, K.R.A., Lamie, P.F., Omar, H.A., 3-Methyl-2-phenyl-1-substituted-indole derivatives as indomethacin analogs: design, synthesis and biological evaluation as potential anti-inflammatory and analgesic agents. J. Enzyme Inhib. Med. Chem. 31 (2016), 318–324.
30. [30] Modi, N.R., Shah, R.J., Patel, M.J., Suthar, M., Chauhan, B.F., Patel, L.J., Design, synthesis, and QSAR study of novel 2-(2,3-dioxo-2,3-dihydro-1H-indol-1-yl)-N-phenylacetamide derivatives as cytotoxic agents. Med. Chem. Res. 20 (2011), 615–625.
31. [31] Behbehani, H., Ibrahim, H.M., 4-Thiazolidinones in heterocyclic synthesis: synthesis of novel enaminones, azolopyrimidines and 2-Arylimino-5-arylidene-4-thiazolidinones. Molecules 17 (2012), 6363–6385.
32. [32] Chen, D., Shena, G., Bao, W., An efficient cascade synthesis of various 2H-1,4-benzoxazin-3-(4H)-ones from o-halophenols and 2-halo-amides catalyzed by CuI. Org. Biomol. Chem. 7 (2009), 4067–4073.
33. [33] Lamie, P.F., Phillopes, J.N., El-Gendy, A.O., Rarova, L., Gruz, J., Design, synthesis and evaluation of novel phthalimide derivatives as in vitro anti-microbial, anti-oxidant and anti-inflammatory agents. Molecules 20 (2015), 16620–16642.
34. [34] Yamamoto, S., Mammalian lipoxygenases: molecular structures and functions. Biochim. Biophys. Acta 1128 (1992), 117–131.
35. [35] Gaffney, B.J., Lipoxygenases: structural principles and spectroscopy. Annu. Rev. Biophys. Biomol. Struct. 25 (1996), 431–459.
36. [36] Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S., Olson, A.J., Autodock 4 and AutoDockTools 4: automated docking with selective receptor flexibility. J. Comput. Chem. 16 (2009), 2785–2791.
37. [37] Trott, O., Olson, A.J., Software News and Update AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31 (2010), 455–461.